5th Jan 2021 16:05
Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics company - Partners with DaVita on a programme aimed at slowing disease progression and improving health outcomes for adults with chronic kidney disease. Programme also aims to provide cost reductions for health care providers by enabling earlier intervention for patients with early-stage kidney disease. Expects collaboration to launch in three major markets in 2021
"This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management right to the primary care level where the majority of kidney disease patients are being seen," said RenalytixAI Chief Executive James McCullough.
Current stock price: 629.50 pence
Year-to-date change: up 29%
By Ife Taiwo; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc